Transplants (Transplant)

Subscribe to Selected New Research on Transplants

69200 relevant articles (3151 outcomes, 5065 trials/studies) found for this Therapy

Description: Organs, tissues, or cells taken from the body for grafting into another area of the same body or into another individual. (From Dorland, 28th ed)

Also Known As:

Transplant; Graft; Organ Transplant; Grafts; Organ Transplants; Tissue Transplant; Tissue Grafts; Tissue Graft; Cell Transplant; Graft, Organ; Graft, Tissue; Grafts, Organ; Grafts, Tissue; Organ Graft; Transplant, Cell; Transplant, Organ; Transplant, Tissue; Transplants, Cell; Transplants, Organ; Transplants, Tissue; Cell Transplants; Organ Grafts; Tissue Transplants

Relationship Network

Therapy Context: Research Results

Equipment and Supplies

Transplants: 69200

Experts

1.	Singh, Nina: 23 articles (10/2008 - 07/2002)
2.	Robbins, Robert C: 18 articles (11/2005 - 04/2002)
3.	Lammer, Johannes: 16 articles (06/2008 - 05/2002)
4.	Rubin, R H: 16 articles (02/2008 - 02/2000)
5.	Kamar, Nassim: 15 articles (04/2008 - 04/2003)
6.	Rostaing, Lionel: 15 articles (04/2008 - 04/2003)
7.	Husain, Shahid: 14 articles (09/2008 - 07/2002)
8.	Haberal, M: 14 articles (01/2008 - 05/2000)
9.	Bacigalupo, A: 14 articles (11/2007 - 06/2000)
10.	Lazarus, Hillard M: 13 articles (10/2008 - 02/2002)

Related Diseases

1.	Infection 08/01/2002 - "Although most CF lung transplant recipients experience both graft infection and rejection and the 5-yr survival rate remains at approx 50%, improvement in diagnosis and therapy continue over time" 03/01/2001 - "The D-/R- group had the best outcomes, with no CMV infection, improved kidney graft survival at the end of follow-up (82% vs. 72%, P=0.04) and the highest event-free survival (no CMV infection, rejection, or graft loss) when compared to the other groups (76% vs. 33%, P<0.01)" 06/01/1999 - "CONCLUSION: Our method of extensive disinfection followed by tissue flap coverage of the graft proved to be highly effective in controlling the serious complication of graft infection associated with surgery of the thoracic aorta." 01/01/1998 - "Extra-anatomic bypass remains the best treatment for prosthetic graft infection" 01/01/1998 - "Debate continues over which procedure is the best treatment for prosthetic graft infections" Order ALL the reference details at left...
2.	Leukemia 07/01/2004 - "The CD8-HDM Cell Separation System appears to be highly selective and effective in depleting CD8+ T cells from DLI apheresis products, and CD8-depleted DLI is capable of mediating a graft-versus-leukemia effect while minimizing GVHD." 02/01/1995 - "Whereas immunomagnetic CD34+ selection is most effective in terms of elimination of T cells, the less intensive T and NK cell depletions achieved with CAMPATH-1 might be advantageous with regard to retaining engraftment potential and graft-vs.-leukemia (GVL) activity of PBPC allografts." 05/10/1979 - "This apparent antileukemic effect was more marked in patients with lymphoblastic than nonlymphoblastic leukemia, and in those who received transplants during relapse rather than during remission, and was most evident during the first 130 days after transplantation" 10/01/2002 - "It is concluded that the models established in this study are stable and direct with an excellent reproducibility and an accuracy, which can be used to evaluate purging efficacy of leukemia cells in model graft using immunomagnetic selection and the experimental studies on tumorcidal effect in vitro." 05/01/2008 - "Significant associations were found between the risk of relapse or the risk of death during complete remission and the leukemia genotype of mutant NPM1 without FLT3-ITD (hazard ratio, 0.44; 95% confidence interval [CI], 0.32 to 0.61), the mutant CEBPA genotype (hazard ratio, 0.48; 95% CI, 0.30 to 0.75), and the MLL-PTD genotype (hazard ratio, 1.56; 95% CI, 1.00 to 2.43), as well as receipt of a transplant from an HLA-matched related donor (hazard ratio, 0.60; 95% CI, 0.44 to 0.82)" Order ALL the reference details at left...
3.	Neoplasms (Cancer) 09/01/2008 - "CONCLUSIONS: Although the heterogeneity of different studies precludes their collection for a meta-analysis, it can be inferred that adoptive therapy with EBV-specific CTL is safe, well tolerated and particularly effective in the case of most immunogenic tumors, like post-transplant lymphoproliferative disease." 06/01/2008 - "While GVHD and graft-versus-tumor (GVT) effects are highly correlated after DLI, some patients experience remission without GVHD" 08/01/2005 - "The cumulative experience over the years suggesting that alloreactive donor lymphocytes were most effective in eliminating tumor cells of host origin resulted in an attempt to reduce the intensity of the conditioning in preparation for the transplant procedure used for the treatment of hematological and other malignancies as well as life-threatening non-malignant disorders for which allogeneic stem cell transplantation may be indicated" 04/01/2004 - "Hepatocellular cancer (HCC) is increasing in incidence and liver transplant (LT) is likely the best treatment for long-term survival and decreased recurrence in those with localized disease" 03/01/2002 - "Liver transplant is the most effective treatment for hepatocellular cancer in the subgroup of smaller tumors, but ultimately we are limited by the number of available donors" Order ALL the reference details at left...
4.	Thrombosis (Thrombus) 10/18/1993 - "In addition to its established efficacy for highly eccentric lesions, newer applications for which DCA is being used following FDA approval include treatment of saphenous vein grafts, thrombus-associated lesions, aorto-ostial lesions, failed or suboptimal percutaneous transluminal coronary angioplasty result, bifurcation lesions, and use as part of multivessel intervention.(ABSTRACT TRUNCATED AT 250 WORDS)" 05/01/2008 - "Recently, rheolytic thrombectomy has been proven to be effective in the treatment of massive thrombosis in vein grafts" 04/01/2001 - "There is a marked risk of acute thrombosis of an ipsilateral arterial bypass graft after TKA that cannot be eliminated by performing the TKA without a tourniquet" 01/01/2000 - "CONCLUSION: A surveillance program helped prevent graft thrombosis, and intervention as required achieved excellent primary and assisted patency rates" 01/01/2000 - "The improved visualization and contrast enhancement were more marked in the grafts that contained thrombus nonhyperechoic to surrounding soft tissues" Order ALL the reference details at left...
5.	Pathologic Constriction (Stenosis) 04/01/2000 - "We find that auricular cartilage grafts are highly effective when used in a primary single-stage procedure in children with grade I or II stenosis" 09/01/1995 - "CONCLUSIONS: Percutaneous techniques are most effective in treating failing but patent angioaccess grafts, especially those with stenoses remote from the venous anastomosis" 12/01/1987 - "Best results were obtained with a discrete stenosis at a graft-to-vein anastomosis" 07/01/1980 - "The results of these studies indicate that: 1) marked stenosis of bypass grafts is needed to decrease coronary flow in the resting state, and even moderate stenosis will decrease flow during exercise when the diameter of the bypass is large relative to the coronary artery; 2) coronary flow is decreased with mild stenosis for bypass grafts of the same diameter as the coronary artery; and 3) a marked decrease in flow due to stenosis of a bypass graft occurs only when the diameter of a stenosis in a graft is less than the diameter of the coronary artery." 02/01/1990 - "Although post-operative early graftgraphy showed LAD graft stenosis, it resolved completely at the second graftgraphy one year after the operation" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Cyclosporine (Ciclosporin)
2.	Polytetrafluoroethylene (Teflon)
3.	Polyethylene Terephthalates (Polyethylene Terephthalate)
4.	Cyclophosphamide (Cytoxan)
5.	Ganciclovir (Cytovene)
6.	Antigens
7.	Anti-Bacterial Agents (Antibiotics)
8.	Tacrolimus (Prograf)
9.	Collagen
10.	Rifampin (Rifampicin)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Transplantation (Transplant Recipients)
3.	Stents
4.	Drug Therapy (Chemotherapy)
5.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 13883 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>